Convulsant bicuculline modifies CNS muscarinic receptor affinity
Patricia G Schneider*1 and Georgina Rodríguez de Lores Arnaiz1,2

Address: 1Instituto de Biología Celular y Neurociencias "Prof. E. De Robertis", Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, 1121-Buenos Aires, Argentina and 2Cátedra de Farmacología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, 1121- Buenos Aires, Argentina

Email: Patricia G Schneider* - patriciaschneider@fibertel.com.ar; Georgina Rodríguez de Lores Arnaiz - grodrig@ffyb.uba.ar

* Corresponding author

Abstract

Background: Previous work from this laboratory has shown that the administration of the convulsant drug 3-mercaptopropionic acid (MP), a GAD inhibitor, modifies not only GABA synthesis but also binding of the antagonist [3H]-quinuclidinyl benzilate ([3H]-QNB) to central muscarinic receptors, an effect due to an increase in affinity without modifications in binding site number. The cholinergic system has been implicated in several experimental epilepsy models and the ability of acetylcholine to regulate neuronal excitability in the neocortex is well known. To study the potential relationship between GABAergic and cholinergic systems with seizure activity, we analyzed the muscarinic receptor after inducing seizure by bicuculline (BIC), known to antagonize the GABA-A postsynaptic receptor subtype.

Results: We analyzed binding of muscarinic antagonist [3H]-QNB to rat CNS membranes after i.p. administration of BIC at subconvulsant (1.0 mg/kg) and convulsant (7.5 mg/kg) doses. Subconvulsant BIC dose failed to develop seizures but produced binding alteration in the cerebellum and hippocampus with roughly 40% increase and 10% decrease, respectively. After convulsant BIC dose, which invariably led to generalized tonic-clonic seizures, binding increased 36% and 15% to cerebellar and striatal membranes respectively, but decreased 12% to hippocampal membranes. Kd value was accordingly modified: with the subconvulsant dose it decreased 27% in cerebellum whereas it increased 61% in hippocampus; with the convulsant dose, Kd value decreased 33% in cerebellum but increased 85% in hippocampus. No change in receptor number site was found, and Hill number was invariably close to unity.

Conclusion: Results indicate dissimilar central nervous system area susceptibility of muscarinic receptor to BIC. Ligand binding was modified not only by a convulsant BIC dose but also by a subconvulsant dose, indicating that changes are not attributable to the seizure process itself. Findings support the notion that the muscarinic receptors play a major role in experimental epilepsy and provide a new example of differential neuronal plasticity.
Convulsant drug administration has proven to be effective and therefore a useful tool to study experimental epilepsy, since it produces behavioral modifications concomitant with marked neurochemical changes. Acetylcholine is an essential neurotransmitter/neuromodulator in several experimental epilepsy disorders [1], and its ability to regulate neuronal excitability in neocortex is well known [2]. Interestingly, the anticonvulsant effect mediated by carbachol microinjection in the nucleus reticularis pontis oralis appears to be mediated by muscarinic receptors [3].

GABA is the major central inhibitory neurotransmitter, and it is not surprising, therefore, that it has been involved in epileptic activity genesis [4-6]. The biosynthesis of GABA requires the activity of glutamic acid decarboxylase (GAD), a cytosolic enzyme that is found in neurons where GABA is a neurotransmitter.

Previous work from this laboratory has shown that the administration of the convulsant drug 3-mercaptotropionic acid (MP), a GAD inhibitor [7], modifies not only GABA synthesis [8,9] but also binding of antagonist [3H]-quinuclidinyl benzilate ([3H]-QNB) to central muscarinic receptors, an effect due to an increase in affinity without modifications in binding site number [10-12].

To study potential relationship between GABAergic and cholinergic systems with seizure activity, we analyzed the muscarinic receptor after inducing seizure by bicuculline (BIC), known to antagonize GABA-A postsynaptic receptor subtype [13]. Subconvulsant and convulsant BIC doses were administered to rats and [3H]-QNB binding to central muscarinic receptors, an effect due to an increase in affinity without modifications in binding site number [10-12].

To examine potential changes in muscarinic receptors, [3H]-QNB binding to rat CNS membranes isolated from control and BIC treated animals was assayed.

**Effect of a subconvulsant BIC dose**

Intraperitoneal rat administration of 1.0 mg/kg BIC failed to develop seizures but slight abnormal behaviour changes as sniffing and intensive washing movements were observed during 5–10 minutes, when animals recovered normal behavior.

Significant changes in [3H]-QNB binding in cerebellum and hippocampus were found. In cerebellum, an increase of roughly 40% was recorded, since ligand binding in pmol per mg protein was 0.50 in BIC treated versus 0.35 in control group. In hippocampus, 10% decrease was obtained, with values of 1.35 in BIC treated versus 1.50 in control group. No significant changes were found in cortical or striatal membranes (Table 1).

**Effect of a convulsant BIC dose**

Intraperitoneal rat injection of 7.5 mg/kg BIC resulted in the development of generalized tonic-clonic seizures. As a rule, after 90–120 sec latency, rats suddenly ran amok (during 10–30 sec), then became motionless, regained tonus (30–45 sec), and ended up with a four-limb clonic phase (90–150 sec). Present experiments were performed with animals decapitated at the onset of seizure, during the running stage.

At seizure stage, [3H]-QNB binding to cerebellar membranes exhibited 36% increase, since ligand binding in pmol per mg protein was 0.46 in BIC treated versus 0.34 in control group. Again, a 12% decrease was observed in hippocampus, with data, in pmol per mg protein, of 1.36 in BIC versus 1.50 in control group. [3H]-QNB binding to striatal membranes increased 15% with values of 2.27 in BIC treated versus 1.98 in control group; no significant changes were found in cortical membranes (Table 2).

**Saturation studies**

In order to determine whether binding changes observed in cerebellum and hippocampus were due to modifications in affinity and/or site number, [3H]-QNB binding was studied at variable ligand concentrations. Saturation values were attained with 0.50–1.00 nM ligand in membranes after subconvulsant and convulsant BIC doses as well as in control membranes (Figs. 2, 3, 4, 5).

Scatchard analysis of [3H]-QNB binding data recorded at equilibrium disclosed a significant decrease (27%) in cerebellum Kd value in membranes obtained from rats treated with 1.0 mg/kg BIC dose; on the contrary, hippocampus Kd value increased 61%. No change in receptor site number was recorded in either area. Hill number was

---

To examine potential changes in muscarinic receptors, [3H]-QNB binding to rat CNS membranes isolated from control and BIC treated animals was assayed.

**Effect of a subconvulsant BIC dose**

Intraperitoneal rat administration of 1.0 mg/kg BIC failed to develop seizures but slight abnormal behaviour changes as sniffing and intensive washing movements were observed during 5–10 minutes, when animals recovered normal behavior.

Significant changes in [3H]-QNB binding in cerebellum and hippocampus were found. In cerebellum, an increase of roughly 40% was recorded, since ligand binding in pmol per mg protein was 0.50 in BIC treated versus 0.35 in control group. In hippocampus, 10% decrease was obtained, with values of 1.35 in BIC treated versus 1.50 in control group. No significant changes were found in cortical or striatal membranes (Table 1).

**Effect of a convulsant BIC dose**

Intraperitoneal rat injection of 7.5 mg/kg BIC resulted in the development of generalized tonic-clonic seizures. As a rule, after 90–120 sec latency, rats suddenly ran amok (during 10–30 sec), then became motionless, regained tonus (30–45 sec), and ended up with a four-limb clonic phase (90–150 sec). Present experiments were performed with animals decapitated at the onset of seizure, during the running stage.

At seizure stage, [3H]-QNB binding to cerebellar membranes exhibited 36% increase, since ligand binding in pmol per mg protein was 0.46 in BIC treated versus 0.34 in control group. Again, a 12% decrease was observed in hippocampus, with data, in pmol per mg protein, of 1.36 in BIC versus 1.50 in control group. [3H]-QNB binding to striatal membranes increased 15% with values of 2.27 in BIC treated versus 1.98 in control group; no significant changes were found in cortical membranes (Table 2).

**Saturation studies**

In order to determine whether binding changes observed in cerebellum and hippocampus were due to modifications in affinity and/or site number, [3H]-QNB binding was studied at variable ligand concentrations. Saturation values were attained with 0.50–1.00 nM ligand in membranes after subconvulsant and convulsant BIC doses as well as in control membranes (Figs. 2, 3, 4, 5).

Scatchard analysis of [3H]-QNB binding data recorded at equilibrium disclosed a significant decrease (27%) in cerebellum Kd value in membranes obtained from rats treated with 1.0 mg/kg BIC dose; on the contrary, hippocampus Kd value increased 61%. No change in receptor site number was recorded in either area. Hill number was
close to unity and remained unaltered in both cerebellar and hippocampal membranes (Table 3).

At seizure stage, $K_d$ value decreased 33% in cerebellum, but increased 85% in hippocampus. No significant change in $B_{\max}$ was found either in cerebellar or hippocampal membranes. Here again, Hill number was close to unity and remained unaltered in either case (Table 4).

Equilibrium binding data for $[^3H]$-QNB recorded at several ligand concentrations were analyzed by a computer to disclose whether a single or two population sites were operative; it was observed that the best fit indicated a single population site.

**Discussion**

To analyze muscarinic receptor under GABA-A receptor blockade, $[^3H]$-QNB binding to rat CNS membranes after the administration of subconvulsant and convulsant BIC doses was studied. The subconvulsant BIC dose produced significant changes in $[^3H]$-QNB binding, with an increase in cerebellar but a decrease in hippocampal membranes, without alterations in either striatal or cortical membranes. With the convulsant BIC dose, binding increased to cerebellar and striatal membranes but decreased to hippocampal membranes whereas it remained unaltered to cortical membranes. Whenever alterations in binding were recorded, they were invariably due to affinity changes alone, since site number remained constant.

Scatchard plots obtained at equilibrium rendered linear profiles and Hill number was close to unity, suggesting that $[^3H]$-QNB binds to a homogeneous site population in all cases.

On the basis of studies performed in diverse animal models, the concept that epileptic episodes may be caused by imbalance between inhibition and excitation inputs has been advanced [1,15-17]. Synaptic inhibition is a regulatory and crucial mechanism which limits the generation of action potential in neurons.

Glutamatergic NMDA receptors are known to exert a role in seizure [18,19]; however, the possible involvement of other receptor types, i.e., muscarinic receptors, has been advanced [4,20-22], among which M1 is the only subtype mediating pilocarpine-induced seizure [23,24].

Several lines of evidence point to a relationship between cholinergic muscarinic activation, GABA system and seizure activity. Previous work from this laboratory has shown that convulsant MP modifies GABA system by decreasing GAD activity and GABA levels as well as altering of cerebellar Purkinje cell morphology [8,9]. With a convulsant MP dose, $[^3H]$-QNB binding to muscarinic receptors is enhanced in CNS, an effect due to an increase in affinity without changes in binding site number [10,11]. However, a subconvulsant MP dose fails to induce any change [10-12]. Herein it is shown that BIC.

### Table 1: Effect of a subconvulsant BIC dose (1.0 mg/kg, i.p.) on $[^3H]$-QNB binding to membranes isolated from four brain areas.

| Area         | Control pmol.mg protein$^{-1}$ | Subconvulsive pmol.mg protein$^{-1}$ | Δ (%) |
|--------------|-------------------------------|-------------------------------------|-------|
| Cerebellum   | $0.35 \pm 0.04 \,(3)$         | $0.50 \pm 0.04^{**} \,(3)$          | + 43  |
| Hippocampus  | $1.50 \pm 0.03 \,(3)$         | $1.35 \pm 0.03^{*} \,(3)$           | - 10  |
| Striatum     | $1.98 \pm 0.11 \,(3)$         | $2.09 \pm 0.05 \,(3)$               | + 6   |
| Cerebral cortex | $1.35 \pm 0.04 \,(3)$        | $1.44 \pm 0.14 \,(3)$               | + 7   |

Values are means ± S.D. Figures in parentheses denote number of separate experiments performed in triplicate.

* $P < 0.05$, ** $P < 0.01$ (Student’s-$t$ test).

### Table 2: Effect of a convulsant BIC dose (7.5 mg/kg, i.p.) on $[^3H]$-QNB binding to membranes isolated from brain areas.

| Area         | Control pmol.mg protein$^{-1}$ | Convulsive pmol.mg protein$^{-1}$ | Δ (%) |
|--------------|-------------------------------|-----------------------------------|-------|
| Cerebellum   | $0.34 \pm 0.03 \,(6)$         | $0.46 \pm 0.03^{**} \,(6)$       | + 36  |
| Hippocampus  | $1.55 \pm 0.07 \,(6)$         | $1.36 \pm 0.08^{*} \,(6)$       | - 12  |
| Striatum     | $1.98 \pm 0.11 \,(3)$         | $2.27 \pm 0.14^{*} \,(3)$       | + 15  |
| Cerebral cortex | $1.35 \pm 0.04 \,(3)$        | $1.42 \pm 0.04 \,(3)$           | + 5   |

Values are means ± S.D. Figures in parentheses denote number of separate experiments performed in triplicate.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ (Student’s-$t$ test).
administration either at subconvulsant or convulsant dose, is able to modify [3H]-QNB binding to muscarinic receptor. Therefore, the explanation that alteration of muscarinic receptor is a consequence of seizure process seems untenable.

The increase in ligand binding to striatal and cerebellar membranes with convulsant BIC dose may well indicate the activation of cholinergic excitatory circuits. These findings are consistent with the observation that muscarinic receptor activation during BIC blockade of GABA-A-mediated potentials induces synchronous epileptiform activity in immature rat CNS [25,26].

Herein we recorded a small but significant decrease in binding in hippocampal membranes obtained with convulsant and subconvulsant BIC doses, an expected result since after short seizure hippocampus undergoes cellular, functional and structural alterations following the administration of convulsant drugs [27-29]. Interestingly, in this epileptogenic area, interactions between cholinergic and GABAergic systems have been documented [16,30-32]. Present results in hippocampus differ from those recorded with convulsant MP [10-12], a finding which may receive an explanation in the different mechanism of action of BIC versus MP.

As regards results recorded in striatum, where binding changes were observed only after BIC convulsant dose, it should be recalled that this area participates in motor activities. In this connection, muscarinic receptor altera-

Table 3: [3H]-QNB binding constants in cerebellar and hippocampal membranes after administration of a subconvulsant BIC dose (1.0 mg/kg).

| Area       | Condition      | Kd (pM)   | ∆ (%) | Bmax (pmol.mg prot⁻¹) | Nh          |
|------------|----------------|-----------|-------|-----------------------|-------------|
| Cerebellum | Control        | 197.5 ± 6.0|       | 0.36 ± 0.08           | 1.01 ± 0.02 |
|            | Subconvulsive  | 144.9 ± 5.5| -27   | 0.42 ± 0.07           | 0.98 ± 0.03 |
| Hippocampus| Control        | 115.4 ± 5.8|       | 2.31 ± 0.09           | 0.97 ± 0.04 |
|            | Subconvulsive  | 185.6 ± 3.9| +61   | 2.38 ± 0.10           | 0.96 ± 0.02 |

For each experiment, cerebellum and hippocampus from five rats were pooled, membranes separated and [3H]-QNB binding assayed. Data from three experiments were processed to calculate constants. Results presented are mean values ± S.D.

**sup** P < 0.001 (Student’s-t test).
tion in striatum is observed after high doses of muscarinic agonist pilocarpine [33].

Among CNS studied areas, cerebellum presents the lowest density of muscarinic receptor sites; however, the greatest changes in [3H]-QNB binding after BIC administration were recorded in this area, attributable to cerebellum participation in motor activity, markedly altered during convulsive activity.

Normal neurophysiological functions as adaptation, inhibition and facilitation, among others, are associated with plasticity, participating in compensatory processes by which the CNS adapts to pathological conditions, exposure to drugs and neuronal damage and loss [34]. Neuronal plasticity evidences the response of a circuit, a neurotransmitter or a receptor that is modified as a result of different factors or altered processes. Herein it is shown that muscarinic receptor changed promptly after stimulus (BIC administration), a finding in line with the observation that this receptor is enhanced in the human epileptic focus at early times following seizures through activity-dependent mechanisms [35].

On comparing previous results obtained with MP versus present findings with BIC, a differential response of muscarinic receptor is evident according to GABA system site alteration, that is, when GAD activity is inhibited or GABA-A receptor antagonized.

Table 4: [3H]-QNB binding constants in cerebellar and hippocampal membranes after administration of a convulsant (7.5 mg/kg) BIC dose.

| Area     | Condition | K_d (pM)   | Δ (%) | B_max (pmol.mg prot⁻¹) | N_H |
|----------|-----------|------------|-------|------------------------|-----|
| Cerebellum | Control   | 200.1 ± 7.1 |       | 0.35 ± 0.01            | 1.00 ± 0.01 |
|          | Convulsive| 133.3 ± 7.5 | -33   | 0.42 ± 0.07            | 1.05 ± 0.02 |
| Hippocampus | Control   | 108.8 ± 2.7 | +85   | 1.75 ± 0.08            | 1.01 ± 0.06 |
|          | Convulsive| 185.6 ± 3.9 |       | 1.72 ± 0.11            | 0.98 ± 0.02 |

For each experiment, cerebellum and hippocampus from five rats were pooled, membranes separated and [3H]-QNB binding assayed. Data from three experiments were processed to calculate constants. Results presented are mean values ± S.D.

***P < 0.001 (Student-t test).
To sum up, results indicate that: 1) seizure activity itself is not the sole mechanism liable to produce a change in muscarinic receptors, since a subconvulsant BIC dose also induces modifications; 2) there is dissimilar area susceptibility for muscarinic receptor to BIC; and 3) muscarinic receptor response to convulsant drugs (MP or BIC) support differential neuronal plasticity. Findings support the notion that muscarinic receptors play a major role in experimental epilepsy.

**Conclusion**
Results indicate dissimilar central nervous system area susceptibility of muscarinic receptor to BIC. Ligand binding was modified not only by a convulsant BIC dose but also by a subconvulsant dose, indicating that changes are not attributable to seizure process itself. Findings support the notion that the muscarinic receptors play a major role in experimental epilepsy and provide a new example of differential neuronal plasticity.

**Methods**

**Animals and drug treatment**
Young adult male Wistar rats (25 days old) weighing 100–150 g were used. Animals caged in groups of five were housed at constant temperature (20–23°C) and maintained at least one week in a 12 h light-dark cycle (from 9.00 a.m. to 9.00 p.m.) with free access to food and water. Rats were injected i.p. between 9.30 and 11.30 a.m. with fresh BIC solutions to reach 1.0 and 7.5 mg/kg doses. BIC (Sigma, St. Louis, MO) was dissolved in 0.1 N HCl, brought to pH 5 with 0.1 N NaOH and immediately injected. All studies described were conducted in accordance with the Guide for Care and Use of Laboratory Animals provided by the National Institutes of Health, USA.

**Experimental groups**
Three experimental groups were used: control, subconvulsant, and convulsant. Animals in the control group received no treatment. In the subconvulsant group, rats were injected with 1 mg/kg BIC dose, a dose which failed to induce seizure or behavioral modifications. In the convulsant group, animals were injected with 7.5 mg/kg BIC, a dose that produced generalized tonic-clonic seizures. For each BIC dose, lots of 5 rats each time with their corresponding controls were used.

Rats were decapitated at 30 min after injection (subconvulsant stage or condition) or at the onset of seizure (convulsant stage or condition), respectively. Each condition was repeated 3–6 times.

Since saline administration produces no change in any of the areas studied [11], uninjected rats were used as controls.

**Membrane preparations**
For each experimental condition cerebellum, hippocampus, cerebral cortex and striatum from five animals were harvested and separately pooled. Tissues were rapidly homogenized at 10% w/v, except for cerebral cortex at 4% w/v, in 0.32 M sucrose neutralized with Tris base solution (0.4 mM Tris final concentration) in a Teflon glass Potter-Elvehjem homogenizer.

Homogenates were centrifuged at 900 g for 10 min and pellets discarded; resulting supernatants were diluted with 0.16 M sucrose to achieve a final concentration of 0.25 M sucrose, centrifuged at 100,000 g for 30 min and membrane pellets stored at -70°C until use.

**[^H]-QNB binding assay**
[^H]-QNB binding was determined according to the method described by Yamamura and Snyder [36] with slight modifications. Membrane pellets were resuspended and later diluted in 50 mM sodium, potassium phosphate buffer (pH 7.4) to reach 0.1 mg protein/ml concentration. Triplicate membrane aliquots were incubated (2 ml final volume) at 30°C in the presence of 0.5 nM L-[^H]-QNB (S-[^H]-QNB enantiomer), Du Pont Corp. New England Nuclear, Boston, MA, USA, specific activity 14,443 GBq/mmol), with or without 5 μM atropine sulfate. Incubation proceeded for 60 min, because[^H]-QNB binding reached
equilibrium after 45 min incubation, in agreement with data from the literature [37-39].

After incubation, 3 ml of ice-cold sodium, potassium phosphate buffer were added and samples vacuum-filtered through Whatman GF/B glass disks. Filters were washed twice with 3 ml of ice-cold buffer, placed in plastic vials and dried overnight at 70°C. To each vial, 3 ml of 0.4% 2,5-diphenyl-oxazole in toluene were added and radioactivity quantified in a liquid scintillation counter.

Specific binding was calculated as the difference between the binding in the absence and presence of 5 µM atropine sulfate, and represented ca 90% of total binding.

Results averaged were obtained with different membranes isolated from tissue pooled (from 5 rats each group). The whole experiment (BIC administration, tissue harvesting, membrane preparation and binding assay in triplicate) was carried out in 3 or 6 different occasions.

For saturation studies, duplicate membrane samples were incubated in the presence of [3H]-QNB ranging from 0.125 to 2.00 nM concentration and processed as described above. The same basic filtration assay was used in experiments in which the kinetics of binding were investigated. For measurement of association rates, cerebral cortex membranes were incubated at 0.1 mg/ml protein concentration, in the presence of 0.5 nM L-[3H]-QNB. At different time intervals extending over 180 min, 3 ml samples were removed and filtered as indicated above. Additional samples were incubated in the presence of 5 µM atropine sulfate to assay nonspecific binding. The measurement of dissociation rates was performed in a similar way on membranes that had reached equilibrium binding after incubation for 60 min in the presence of 0.5 nM L-[3H]-QNB.

Protein was assayed according to Lowry et al. [40] using bovine serum albumin as standard.

Data analysis
Differences in mean values between groups were evaluated by Student’s-t test. Significance levels were set at P<0.05.

For saturation assays, non-linear regression of the data were processed using EDBA program (G. A. Mc Pherson 1983 V 2.0). Scatchard transformation of the data obtained at equilibrium was employed to show whether more than one receptor population was operative.

Authors' contributions
PGS and GRLA participated conjointly in the design, performing assays and writing the manuscript. The authors read and approved the final manuscript.

Acknowledgements
G. R. de L. A. is chief investigator from the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). This study was supported by grants from the Agencia Nacional de Promoción Científica y Tecnológica, CONICET and Universidad de Buenos Aires, Argentina.

References
1. Wasterlain CG, Farber DB, Fairchild MD: Synaptic mechanisms in the kindled epileptic focus: a speculative synthesis. In Advances in Neurology Edited by: Delgado-Escueta AV, Ward AA Jr, Woodbury DM, Porter RJ. New York: Raven Press; 1986:411-433.
2. Cox CL, Metherate R, Ashe JH: Modulation of cellular excitability in neocortex: modulation of messenger-mediated actions of acetylcholine. Synapse 1994, 16:123-136.
3. Peterson SL, Armstrong JJ: Muscarinic receptors mediate carbachol-induced inhibition of maximal electroshock seizures in the nucleus reticularis pontis oralis. Epilepsia 1999, 40:20-25.
4. Meldrum BS: The role of glutamate in epilepsy and other CNS disorders. Neurology 1994, 44:S14-S23.
5. Meldrum BS: Neurotransmission in epilepsy. Epilepsia 1995, 36:30-35.
6. Ribak CE: Epilepsy and the cortex. In Cerebral Cortex Edited by: Peters A. New York: Plenum Publishing Co; 1991:427-483.
7. Sprince H, Parker CM, Josephs J, Magazino J: Convulsant activity of homocysteine and other short-chain mercaptoacids: protection therforeorn. Ann N Y Acad Sci 1969, 166:322-325.
8. Rodriguez de Lores Arnaiz G, Alberici de Canal M, De Robertis E: Alteration of GABA system and Purkinje cells in rat cerebellum by the convulsant 3-mercaptopyrropionic acid. J Neurochem 1972, 19:1379-1385.
9. Rodriguez de Lores Arnaiz G, Alberici de Canal M, Robiolo B, Mistromorio de Pacheco M: The effect of the convulsant 3-mercaptopropionic acid on enzymes of the γ-aminobutyrate system in the rat cerebral cortex. J Neurochem 1973, 21:615-623.
10. Schenieder PG, Girardi ES, Rodriguez de Lores Arnaiz G: 3-mercaptopropionic acid administration increases the affinity of [3H]-quinucleotylin benzilate binding to membranes of the striatum and cerebellum. Neurochem Int 1992, 20:591-597.
11. Schenieder PG, Rodriguez de Lores Arnaiz G: Area-dependent CNS membranes response of muscarinic receptor to convulsant 3-mercaptopyrropionic acid. Mol Chem Neuropharmacol 1997, 32:1-9.
12. Schenieder PG, Rodriguez de Lores Arnaiz G: Ligand binding to CNS muscarinic receptor is transiently modified by convulsant 3-mercaptopropionic acid administration. Neurochem Res 2000, 25:637-643.
13. Olsen RW, DeLorey TM: GABA and glycine. In Basic Neurochemistry Edited by: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. New York: Lippincott-Raven; 1999:335-346.
14. Chang Kj, Jacobs S, Cuatrecasas P: Quantitative aspects of hormone-receptor interactions. Effect of receptor and messenger-mediated action and measurement of dissociation constants of labeled and unlabeled hormones. Biochim Biophys Acta 1975, 406:294-303.
15. Houser CR: GABA neurons in seizure disorders; a review of immunocytochemical studies. Neurochem Res 1991, 16:295-300.
16. Ribak CE, Peterson GM, Roberts RC: Two abnormal GABAergic circuits in experimental models of epilepsy: morphological correlates of human epilepsy. In Intractable Epilepsy Edited by: Schmidt D, Morselli PL. New York: Raven Press; 1986:61-73.
17. Roberts E: Failure of GABAergic inhibition: a key to local and global seizures. In Advances in Neurology Edited by: Delgado-Escueta AV, Ward AA Jr, Woodbury DM, Porter RJ. New York: Raven Press; 1986:319-341.
18. Dingledine R, McBain CJ: Glutamate and aspartate. In Basic Neurochemistry Edited by: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. New York: Lippincott-Raven; 1999:315-333.
19. Pennell PB, Burdette DE, Ross DA, Henry TR, Albin RL, Sackellares JC, Frey KA: Muscarinic receptor loss and preservation of pre-synaptic cholinergic terminals in hippocampal sclerosis. Epilepsy 1999, 40:38-46.
20. Hwa GGC, Avoli M, Oliver A, Villeumue JG: Bicuculline-induced epileptogenesis in the human neocortex maintained in vitro. Exp Brain Res 1991, 83:329-339.
21. Masukawa LM, Higashima M, Hart GI, Spencer DD, O’Connor MJ: NMDA receptor activation during epileptiform responses in the dentate gyrus of epileptic patients. Brain Res 1991, 562:176-180.
22. Zia-Gharib F, Webster RA: Effect of compounds modulating amino acid neurotransmission on the development and control of bicuculline-induced epileptogenic spiking in the rat. Neuropharmacology 1991, 30:995-1009.
23. Hamilton SE, Loose MD, Qi M, Levey AI, Hille B, McKnight GS, Idzerda RL, Nathanson NM: Disruption of the M1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc Natl Acad Sci USA 1997, 94:13311-13316.
24. Bymaster FP, Carter PA, Yamada M, Gomeza J, Wess J, Hamilton SE, Nathanson NM, McKinzie DL, Felder CC: Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci 2003, 17:1403-1410.
25. Posner S, Psarropoulou C: Endogenous acetylcholine facilitates epileptogenesis in immature rat neocortex. Neurosci Lett 2001, 302:25-28.
26. Psarropoulou C, Dallaire F: Activation of muscarinic receptors during blockade of GABA(A)-mediated inhibition induces synchronous epileptiform activity in immature rat hippocampus. Neuroscience 1998, 82:1067-1077.
27. Khruchatskisky M, Ferhat L, Charton G, Bernard A, Polard H, Represa A, Ben-Ari Y: Molecular correlates between reactive and development plasticity in the rat hippocampus. J Neurobiol 1993, 26:426-436.
28. Millan MH, Chapman AG, Meldrum BS: Extracellular amino acid levels in hippocampus during pilocarpine-induced seizures. Epilepsy Res 1993, 14:39-148.
29. Sutula TP: Reactive changes in epilepsy: cell death and axon sprouting induced by kindling. Epilepsy Res 1991, 10:62-70.
30. Kayadjianian N, Gioanni H, Ménetrey A, Besson MJ: Muscarinic receptor stimulation increases the spontaneous [3H]-GABA release in the rat substantia nigra through muscarinic receptors localized on striatonigral terminals. Neuroscience 1994, 63:989-1002.
31. Marchi M, Sanguineti P, Raitieri M: Muscarinic receptors mediate direct inhibition of GABA release from rat striatal nerve terminals. Neurosci Lett 1990, 116:347-351.
32. Vella N, Ferraro G, Caravaglios A, Aloisi A, Sabatino M, La Grutta V: A feature of caudate control of focal hippocampal epilepsy: evidence for an anterograde pathway. Exp Brain Res 1991, 85:240-242.
33. Mendes Freitas R, Bezerra Felipe CF, Nascimento VS, Oliveira AA, Viana GSB, Foneteles MM de F: Pilocarpine-induced seizures in adult rats monamine content and muscarinic and dopaminergic receptor changes in the striatum. Comp Biochem Physiol Part C 2003, 136:103-108.
34. Pedigo NW Jr: Neurotransmitter receptor plasticity in aging. Life Sci 1994, 55:1985-1991.
35. Ondarza R, Trejo-Martines D, Corona-Amexza R, Briones M, Rocha L: Evaluation of opiod and muscarinic receptors in human epileptogenic neocortex: an autoradiography study. Epilepsia 2002, 43:230-234.
36. Yamamura HY, Snyder SH: Muscarinic cholinergic binding in rat brain. Proc Natl Acad Sci USA 1974, 71:1725-1729.
37. Aguilar JS, Fonseca MI, Lunt GG: Differential effect of ethanol on muscarinic cholinergic binding to rat and locust neural membranes. Neurochem Res 1989, 14:763-770.
38. Waelsbroeck M, Tastenoy M, Camus J, Christophe J: Binding kinetics of quinuclidinyl benzilate and methyl-quinuclidinyl benzilate enantiomers at neuronal (M1), cardiac (M2), and pancreatic (M3) muscarinic receptors. Mol Pharmacol 1991, 40:413-420.
39. Honda K, Takano Y, Kamiya H: Changes in [3H]-quinuclidinyl benzilate binding and protein synthesis in the striatum following chronic administrations of muscarinic agonist. Jpn J Pharmacol 1995, 67:83-86.
40. Lowry OH, Rosebrough N, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.

Publish with BioMed Central and every scientist can read your work free of charge.

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime." Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp